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Summary
Fibronectin glomerulopathy (GFND) is a newly recog-
nized autosomal dominant disease of the kidney that
results in albuminuria, microscopic hematuria, hyper-
tension, renal tubular acidosis type IV, and end-stage
renal disease in the 2d to 6th decade of life. The disease
is characterized histologically by massive deposits of fi-
bronectin (Fn) present in the subendothelial spaces of
renal glomerular capillaries. The cause of human GFND
is unknown. In order to localize a candidate gene for
GFND, we performed linkage analysis of a large, 193-
member pedigree containing 13 affected individuals.
Since we had previously excluded the genes for Fn and
uteroglobin as candidate genes for GFND, a total-ge-
nome search for linkage was performed. Examination
of 306 microsatellite markers resulted in a maximum
two-point LOD score of 4.17 at a recombination frac-
tion of .00 for marker D1S249, and a maximum mul-
tipoint LOD score of 4.41 for neighboring marker
D1S2782. By detection of recombination events, a crit-
ical genetic interval of 4.1 cM was identified, which was
flanked by markers D1S2872 and D1S2891. These find-
ings confirm that GFND is a distinct disease entity
among the fibrillary glomerulopathies. Gene identifica-
tion will provide insights into the molecular interactions
of Fn in GFND, as well as in genetically unaltered
conditions.
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Introduction
Glomerular fibrillary deposits have been described in
three different disease entities: amyloidosis, immunotac-
toid glomerulonephritis, and fibrillary glomerulopathy
(Alpers et al. 1987; Korbet et al. 1991, 1994; Alpers
1992, 1993; Fogo et al. 1993; Hildebrandt and Vollmer
1998). Fibronectin glomerulopathy (GFND; MIM
601894) is a newly recognized autosomal dominant kid-
ney disease, which has been distinguished from these
other disease entities by the presence of glomerular fi-
brillary deposits that show strong immune reactivity to
fibronectin (Fn; Strøm et al. 1995). Patients with GFND
develop albuminuria, microscopic hematuria, arterial
hypertension, renal tubular acidosis type IV, and end-
stage renal disease (ESRD) in the 2d to 6th decade of
life, which necessitates renal replacement therapy by di-
alysis or renal transplantation (Strøm et al. 1995). Al-
though individual unrelated families with GFND have
been reported elsewhere (Bu¨rgin et al. 1980; Tuttle et
al. 1987; Abt et al. 1991; Mazzucco et al. 1992; Ass-
mann et al. 1995), the condition was recognized as a
new disease entity by Strøm et al. (1995), after the his-
tologic findings were reexamined in all six reported fam-
ilies. The genetic defect in GFND is unknown.
Renal histology examination reveals glomeruli that
are enlarged, with minimal hypercellularity and with the
presence of giant fibrillary deposits in the renal glomer-
ular capillaries (Bu¨rgin et al. 1980). Electron microscopy
examination reveals that the deposits are mainly located
in the subendothelial space but are also in the subepi-
thelial and intramembranous spaces. There is only scant
immunoreactivity for immunoglobulins or for comple-
ment factors C1, C3, and C4. However, deposits are
strongly immunoreactive for antibodies to Fn (Strøm et
al. 1995). Fn is an adhesive, high–molecular weight gly-
coprotein that is found in extracellular matrices, such as
the glomerular basement membrane. Fn takes part in
cellular proliferation, wound healing, and platelet ag-
gregation. Because Fn stimulates endocytosis and pro-
motes the clearance of particulate material from the cir-
culation, it has been suggested to function in the
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Figure 1 Kaplan Meier analysis of renal death in 10 patients
from the large GFND kindred. In 10 of 13 affected individuals, data
on onset of ESRD were available. Start of renal replacement therapy
or death as a result of uremia was defined as “renal death.” Three
patients were censored, since renal death did not occur during the
observation period. (Censoring is indicated by vertical strokes without
a drop in the survival curve.) Patient 544, who is affected by GFND,
was censored at age 32 years, for normal creatinine clearance of 98
ml/min; patient 465 was censored at age 37 years, when death occurred
as a result of a nonrenal cause; and patient 462, who is affected by
GFND, was censored at age 58 years, when creatinine clearance was
reduced only to 57 ml/min. The median “renal survival time” was 47
years (range 34–59 years). A curve was fitted manually (dotted line)
for estimation of liability classes (see Patients and Methods). Entries
(vertical strokes) represent patients in the following order: individuals
544, 311, 465, 461, 452, 468, 451, 454, 462, and 463 (see fig. 4).
clearance of C1q-coated material, such as immune com-
plexes or cellular debris (Bing et al. 1982).
In the large GFND kindred examined in this study,
samples studied by use of electron microscopy were
clearly fibrillary and consisted of nonoriented 12#
–nm fibers (Bu¨rgin et al. 1980). In immunolocali-125
zation studies, the fibrillary deposits stained positively
with use of an antibody detecting both plasma-derived
Fn and cellular Fn but were only weakly positive with
use of an antibody detecting only cellular Fn. The fibrils,
therefore, were identified as deposits of plasma-derived
Fn (Strøm et al. 1995). In one patient, the Fn deposits
recurred in a transplanted kidney, although there was
no indication of systemic deposition of Fn (Gemperle et
al. 1996). These findings strongly suggested a molecular
defect in the binding behavior of circulating Fn that in-
fluenced its glomerular handling, which led to renal
glomerular deposition of Fn.
In a recent study by Zhang et al. (1997), a mouse
model of targeted gene disruption of the uteroglobin
(UG) gene was described. In this animal model, mice
developed severe renal disease in association with mas-
sive gomerular deposits of Fn. The distribution of these
deposits and the clinical course were highly reminiscent
of human GFND. The molecular mechanism by which
UG normally prevents Fn deposition in the glomerulus
appears to involve high-affinity binding of UG to Fn, in
circulating blood, to form Fn-UG heteromers. These Fn-
UG heteromeric complexes were shown to counteract
Fn self-aggregation, which resulted in abnormal renal
glomerular Fn deposition in this knockout-mouse model.
The striking similarity between the Fn-UG knockout-
mouse model and human GFND raised the possibility
that an analogous pathogenic mechanism may underlie
GFND. In a previous study of a mouse model of targeted
disruption of the UG gene, the same phenotype had not
been observed (Stripp et al. 1996). We previously had
examined the hypothesis that a genetic defect in the
genes for Fn or UG was responsible for GFND. By use
of haplotype analysis of the large GFND pedigree re-
ported here, we excluded the genes for Fn, villin, and
desmin, as well as the UG gene, from being the causative
genes for GFND (Hildebrandt et al. 1996; Vollmer et
al. 1998).
In the present study, therefore, we conducted a total-
genome search for linkage, which resulted in the local-
ization of a gene locus for GFND to a 4.1-cM genetic
interval, between markers D1S2872 and D1S2891, on
chromosome 1q32, with a maximum multipoint LOD
score (Zmax) of 4.41 for marker D1S2782. These findings
confirm GFND as a distinct disease entity. Gene iden-
tification will provide insights into the molecular inter-
actions of Fn in GFND, as well as insights into the nor-
mal function of Fn.
Patients and Methods
Patients
Selected patients from the 193-member, five-genera-
tion GFND pedigree examined in this study were initially
described by Bu¨rgin et al. (1980). We collected blood
samples from 99 individuals from this pedigree, for iso-
lation of genomic DNA, after we obtained informed con-
sent. The clinical course of 157 individuals of this kin-
dred, 13 of whom were affected by GFND, was
described in a 15-year follow-up study by Gemperle et
al. (1996). Histological aspects of these subjects have
been described elsewhere (family F in Strom et al. 1995).
Segregation of GFND in this pedigree is consistent with
autosomal dominant inheritance and exhibits age-re-
lated penetrance.
Thirteen relatives had developed ESRD based on
GFND. The definition of affected status, as described by
Bu¨rgin et al. (1980), was made on the basis of a biopsy
sample compatible with GFND from nine of the affected
individuals. For the other four individuals (201, 411,
305, and 311), the clinical history was clearly compatible
with an affected status. For the definition of absence of
GFND symptoms, the following criteria had to be met:
(1) absence of significant proteinuria; (2) normal blood
pressure (!140/90 mm Hg), adjusted for age in children;
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Figure 2 a, Genetic map of the GFND region on chromosome
1q32. Microsatellite markers are left of the map axis, and sex-averaged
genetic distances (centimorgans) are to the right. Flanking markers are
underlined. cen  centromere, and tel  telomere. b, Recombinant
events, identified by haplotype analysis (see fig. 4). The haplotype
associated with GFND disease status is represented by a blackened
bar; the haplotype associated with the unaffected status is represented
by an unblackened bar. Individual numbers and symbols for sex and
affected status are shown below the bars (see fig. 4). Flanking markers
D1S2872 and D1S2891 are defined by recombinant events in individ-
uals 307 and 544, respectively. Markers are underlined and connected
to haplotype bars by solid or dotted lines to indicate certain or potential
flanking markers, respectively.
(3) normal renal function (plasma creatinine concentra-
tion !1.0 mg/dl and creatinine clearance 1120 ml/min),
adjusted for age in children; and (4) normal urine sed-
iment (Gemperle et al. 1996). In one patient (452; see
fig. 4), the disease recurred in the renal allograft after
transplantation, and another patient (463) developed or-
gan-limited renal cell carcinoma, as did his unaffected
younger sister (467; Gemperle et al. 1996). In three ad-
ditional patients, the disease had not yet recurred 13, 4,
and 2 years after renal transplantation.
Linkage Analysis
Linkage analysis was performed by use of 297 micro-
satellite markers from the Max–Delbru¨ck Center–
microsatellite set, with an average spacing of 11 cM (M.
Jung, personal communication), and by use of 9 addi-
tional microsatellites, for further fine mapping (Dib et
al. 1996). Genomic DNA was isolated, by use of stan-
dard methods (Sambrook et al. 1989), directly from
blood samples or was isolated after Epstein-Barr virus
(EBV) transformation of peripheral blood lymphocytes
(Steel et al. 1977). Microsatellite markers were amplified
individually by use of an MJ Research Multicycler
PTC225 Tetrad (Biozym). After pooling, markers were
separated by use of an ABI377XL DNA sequencer using
GENESCAN software, as described elsewhere (Hilde-
brandt et al. 1993b; Saar et al. 1997).
For GFND an autosomal dominant mode of inheri-
tance with age-related penetrance was assumed on the
basis of clinical and pedigree data (Strom et al. 1995).
Two-point LOD scores between the disease locus and
microsatellite markers were calculated by use of the
MLINK subroutine of the computer program package
LINKAGE 5.01 (Lathrop et al. 1984). The gene fre-
quency of GFND was set at .0001. The ILINK com-
ponent of the LINKAGE package was used to calculate
Zmax and maximum recombination fractions (vmax). Non-
parametric linkage analysis was performed by use of
GENEHUNTER (Kruglyak et al. 1996). To conduct
multipoint linkage analysis, the program VITESSE was
used (O’Connell and Weeks 1995). Intermarker dis-
tances were taken from Dib et al. (1996), and further
ordering of microsatellite markers was performed by use
of sequence tagged–site (STS) content mapping of CEPH
YAC clones (data not shown). Haplotype analysis was
evaluated graphically (see fig. 4) by use of CYRILLIC,
version 2.1.3 (Cherwell Scientific).
In accordance with the data on age-related penetrance
in this pedigree (fig. 1), liability classes were assigned as
follows: Affected subjects with GFND and unaffected
subjects of the second generation were assigned liability
class 1, with the penetrance vector {.0, .0, .0}. Unaffected
individuals in the third or fourth generation were as-
signed liability class 2, with penetrance vector {.0, .95,
1.0}, if the individual was 150 years of age. Liability
class 3, with penetrance vector {.0, .70, .0}, was assigned
if the individual was !50 years of age.
Results
A subset of the large GFND pedigree, of 13 affected
individuals and 55 individuals without symptoms of
GFND, was employed in the linkage analysis using a
total-genome search. Fifteen years after the initial de-
scription made by Bu¨rgin (1980), individuals of the large
GFND pedigree had been reexamined for the presence
or absence of GFND symptoms (Gemperle et al. 1996),
in accordance with the criteria described in Patients and
Methods. For the present study, 20 individuals of the
youngest generation (all39 years of age), who showed
no symptoms of GFND in the previous study, were re-
examined for affection status, by use of the same criteria.
At reexamination, there was low-grade proteinuria in
three individuals (481, 571, and 551). In one patient
(481), there was arterial hypertension, and in two pa-
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Figure 3 Multipoint linkage analysis of the large GFND pedigree. Six marker loci were calculated versus a GFND locus, by use of
VITESSE. Vertical dashed lines indicate positions of microsatellite markers (see fig. 2a). Intermarker distances were taken from the report by
Dib et al. (1996) and from STS content mapping of CEPH YAC clones (data not shown). For marker D1S2782, , as indicated.Z  4.413max
tients (592 and 545), there was insufficient data for clas-
sification. Because low-grade proteinuria is known not
to cosegregate with the disease status (Gemperle et al.
1996), these data are not sufficient for diagnosis of
GFND. Therefore, no additional information regarding
affected status can be derived from these data.
Age-Related Penetrance
Because of age dependency for the development of
ESRD in GFND, the absence of ESRD cannot be deter-
mined with certainty before age 60 years. We therefore
related disease penetrance to age in this large GFND
pedigree. Kaplan Meier survival analysis of “renal
death” was performed for 10 of the 13 affected indi-
viduals of the large GFND pedigree, for whom data for
onset of ESRD was available (fig. 1). Start of renal re-
placement therapy or death as a result of uremia was
defined as “renal death.” Three patients were censored,
since renal death did not occur during the observation
period. The median “renal survival time” was 47 years
(range 34–59 years). A curve was fitted to the survival
function, which showed a homogeneous, symmetric, sig-
moidal shape for the time course of development of
ESRD in this family.
Total-Genome Search
A total-genome search using 297 microsatellite mark-
ers from the MDC-marker set (M. Jung, personal com-
munication) was performed, as described elsewhere
(Saar et al. 1997), in a subset of the large GFND ped-
igree, which contained 13 affected individuals and 55
individuals without symptoms for GFND. The highest
two-point LOD score, as detected by LODVIEW as a
screening procedure (Hildebrandt et al. 1993a), was
1.65 ( ) at marker D1S419. For fine mapping ofv  .05
this candidate region, nine additional microsatellite
markers in this region (Dib et al. 1996) were genotyped.
Intermarker distances were taken from the report by Dib
et al. (1996). These markers span an interval of 33.8
cM, a sex-averaged genetic distance, on chromosome
1q32, in the following order: cen–D1S2816–1.3
cM–D1S413–2.7 cM–D1S2615–3.8 cM–D1S510–1.6
cM–D1S2872–0.5 cM–D1S249–2.2 cM–D1S2782–1.4
cM–D1S2891–8.5 cM–D1S419–11.8 cM–D1S251–tel
(fig. 2a).
Since there was age dependency for the development
of ESRD, liability classes were assigned according to age
at examination, as described in Patients and Methods.
In addition, an “affected-only” strategy was used, which
is most robust against age-related penetrance, at the ex-
pense of informativity. Two-point linkage analysis re-
sulted in ( ) for marker D1S249 (ta-Z  4.17 v  .00max
ble 1). We thus generated significant evidence for linkage
of a GFND locus to this genetic region on human chro-
mosome 1q. When the affected-only strategy was used,
a ( ) for marker D1S249 was ob-Z  2.1 v  .00max
tained. Haplotype analysis with six microsatellite mark-
ers, by use of VITESSE, yielded for markerZ  4.41max
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Table 1
Pairwise LOD Scores Reflecting Linkage Between Chromosome 1q Loci and GFND
LOCUS
LOD SCORE AT v
Zmax (AT
vmax).00 .01 .05 .1 .2 .3
D1S2816 .181 .199 .251 .282 .275 .211 .282 (.1)
D1S413 .432 .455 .533 .597 .620 .518 .620 (.2)
D1S2615 1.338 1.325 1.271 1.189 .966 .656 1.338 (.0)
D1S510 1.053 .757 .256 .011 .220 .243 .243 (.3)
D1S2872  1.168 .347 .013 .262 .243 .262 (.2)
D1S249 4.173 4.117 3.877 3.544 2.771 1.849 4.173 (.0)
D1S2636 .764 .757 .722 .663 .511 .317 .764 (.0)
D1S2782 2.365 2.368 2.363 2.286 1.926 1.356 2.368 (.01)
D1S2796 1.577 1.552 1.449 1.307 .990 .646 1.577 (.0)
D1S2685 2.273 2.246 2.126 1.956 1.547 1.046 2.273 (.0)
D1S2692 2.948 2.928 2.823 2.638 2.113 1.418 2.948 (.0)
D1S2891  2.074 2.531 2.505 2.068 1.390 2.531 (.05)
D1S419 2.719 2.679 2.510 2.276 1.730 1.088 2.719 (.0)
D1S251 7.353 4.698 2.625 1.693 .782 .325 .325 (.3)
NOTE.—LOD scores were calculated at various vs, by use of liability classes, as described
in Patients and Methods.
D1S2782, which is adjacent to marker D1S249 (fig. 3).
Nonparametric linkage analysis using GENEHUNTER
yielded for marker D1S249 (data notZ  8.0max
shown).
Definition of Flanking Markers
When haplotype analyses were evaluated (fig. 4), a
proximal recombination event was detected for marker
D1S2872 in individual 307, who is unaffected by GFND
at age 86 years, and a distal recombination event was
detected for marker D1S2891 in affected individual 544
(fig. 2b). Therefore, these two markers define a critical
interval for GFND of 4.1 cM of sex-averaged genetic
distance. In addition, closer definition of flanking mark-
ers would be possible if the affected status for individual
545 was known. However, in the absence of symptoms
for GFND at age 33 years, the affected status of this
individual cannot be determined with certainty. If this
subject was affected, marker D1S2782 would be iden-
tified as a closer distal-flanking marker. If this individual
was unaffected, marker D1S2636 would be identified as
a closer proximal-flanking marker.
Marker D1S2782, which exhibited the highest Zmax,
is positioned on CEPH YAC clones 908_e_12 (1,230
kb) and 928_b_8 (1,190 kb) (Whitehead/MIT Center
for Genome Research). In addition to this marker, we
localized, by use of STS content mapping, several ex-
pressed sequence tags (ESTs) for genes of the regulation
of complement activation (RCA) gene cluster to these
two YAC clones (data not shown). Among these were
EST WI-17154, for the decay-accelerating factor for
complement (DAF) gene; EST SGC35372, for the com-
plement component (3b/4b) receptor-1 (CR1) gene; and
EST M26021, for the complement component (3d/EBV)
receptor-2 (CR2) gene. All three genes had been localized
previously to 1q32 (Weis et al. 1984; Lemons et al.
1987). ESTs and polymorphic markers were positioned,
by use of STS content mapping, in the region of overlap
between both YAC clones (908_e_12 and 928_b_8), in
the following order: cen–M26021–WI–17154–
DAF–CR2–D1S2782–D1S2796–SGC35372–CR1–
SHGC12033–MCP–D1S2891–tel.
The gene for factor H, another regulator of comple-
ment activation, was localized outside of the critical in-
terval, by STS content mapping (data not shown). From
the data presented, we concluded that a gene locus for
GFND in this family is localized within a 4.1-cM interval
on chromosome 1q32, between markers D1S2872 and
D1S2891, in close vicinity to the RCA gene cluster. These
findings confirm GFND as a distinct disease entity
among the fibrillary glomerulopathies.
Discussion
In a large GFND pedigree that has been extensively
characterized clinically, we performed linkage analysis
by using a total-genome search strategy, which resulted
in chromosomal localization of a gene locus for GFND
to chromosome 1q32, with for markerZ  4.41max
D1S2782. The 4.1-cM critical genetic interval for GFND
was flanked by markers D1S2872 and D1S2891, and
contained the RCA gene cluster.
The age at onset of early symptoms, as well as the
age at onset of terminal renal failure, seems to vary
among the different GFND pedigrees described in the
literature and seems to be relatively consistent within the
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same family. In the families reported by Abt (1991),
Tuttle (1987), and Mazzucco (1992), terminal renal fail-
ure developed at ages 20–40 years, whereas in the large
pedigree studied here, terminal renal failure clearly
showed a later age at onset, between 34–59 years.
Pathogenetic Hypothesis
In GFND, several histologic and clinical characteris-
tics indicate a genetic defect leading to altered binding
behavior of circulating Fn. (1) Strong immunostaining
with antibodies against plasma-derived Fn was a con-
sistent finding in the GFND families described (Strøm
et al. 1995). (2) The recurrence of disease in one trans-
planted kidney in individual 452 indicates that the ge-
netic defect manifests itself independently of expression
of the defective gene product in the kidney. This points
to a genetic defect in a circulating factor, which might
interfere with the glomerular handling of the deposited
material. (3) UG knockout mice developed severe renal
disease with massive glomerular deposits of Fn, with a
clinical time course and deposit distribution highly rem-
iniscent of human GFND (Zhang et al. 1997). Although
there is no UG expression in the kidney, Zhang and
colleagues demonstrated that UG normally prevents Fn
deposition in the glomerulus through high-affinity bind-
ing of UG to Fn in circulating blood, to form Fn-UG
heteromers. These Fn-UG heteromeric complexes were
shown to counteract Fn self-aggregation, which resulted
in abnormal renal Fn deposition. Because the UG gene
has been excluded as causative for GFND in this pedi-
gree (Vollmer et al. 1998), we postulate that the genetic
defect lies in the gene for another protein that leads to
the intramembranous trapping of Fn in the glomerular
basement membrane, through altered Fn-binding prop-
erties, and, as a result, to the clinical sequelae of GFND.
Candidate Genes
The critical genetic region defined by this study con-
tains the RCA gene cluster, which under this hypothesis
contains several candidate genes for GFND, such as the
DAF, CR1, and CR2 genes. Several lines of evidence
point toward a gene from the RCA cluster as a candidate
gene for GFND. (1) Renal histology in GFND is very
similar to that in other forms of membranoproliferative
(mesangiocapillary) glomerulonephritis (MPGN), with
predominance of subendothelial deposits (Bu¨rgin et al.
1980; Gemperle et al. 1996). (2) MPGN type II is as-
sociated in ∼70% of cases, with constant hypocomple-
mentemia of factors C3, C5, and properdin, through
alternate pathway activation by C3 nephritic factor. At
the microscopic level, there are dense deposits of un-
known origin, which stain mainly for the presence of
C3 in the glomerular basement membrane, as well as in
the subendothelial and subepithelial spaces. In contrast,
in MPGN types I and III, there is stimulation of the
classic pathway, with low serum C1q, C2, and C4, along
with C3. In MPGN, low serum C3 levels have been
implicated in retardation of the normal clearing of im-
mune complexes from the circulation (McEnery and
Strife 1984; Barbiano di Belgiojoso and Ferrario 1997).
(3) Compound heterozygote loss-of-function mutations
of factor H, another regulator of complement activation,
have been described in a patient with MPGN type II
(Ault et al. 1997). However, we localized the gene for
factor H outside the critical GFND region.
These findings strongly suggest a role of a gene from
the RCA cluster as a candidate gene for GFND. Gene
identification in GFND will provide insights into the
molecular interactions of Fn in the diseased state of
GFND, as well as under genetically unaltered conditions.
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